Renaissance Technologies Q1 2026 Performance Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
Source: seekingalpha
- Quarterly Performance: Renaissance Technologies reported a return of -4.58% in Q1 2026, slightly outperforming the S&P 500's decline of 4.63%, indicating its relative resilience despite overall market downturns.
- Portfolio Size: The latest 13F filing reveals a long equity portfolio valued at approximately $63.9 billion across more than 3,200 positions, reflecting the firm's highly diversified and systematic investment strategy.
- Major Holdings: During Q1 2026, the firm's largest holding was United Therapeutics (NASDAQ:UTHR), accounting for 1.66% of the portfolio with a market value of about $1.06 billion, highlighting its significant exposure in the healthcare sector.
- Quant Rating Analysis: Seeking Alpha ranked Renaissance's top 15 holdings, with Micron Technology (MU) receiving a strong buy rating of 4.99, indicating that the company's investments in the tech sector are widely recognized for their potential by the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UTHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UTHR
Wall Street analysts forecast UTHR stock price to fall
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 562.090
Low
423.00
Averages
534.50
High
645.00
Current: 562.090
Low
423.00
Averages
534.50
High
645.00
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
United Therapeutics Corporation Ranked Top Stock by Renaissance Technologies
- Portfolio Performance: According to Renaissance Technologies' 13F filings, United Therapeutics Corporation (NASDAQ:UTHR) has consistently appeared in its portfolio since Q4 2014, currently holding nearly 1.8 million shares, although this represents a decrease of over 6% from Q4 2025.
- Clinical Research Breakthrough: The company is making significant strides in the idiopathic pulmonary fibrosis (IPF) space, with the latest TETON study data showing that nebulized Tyvaso significantly improved lung function over 52 weeks, highlighting its potential in the treatment landscape.
- FDA Submission Preparation: Management noted that due to the positive feedback from TETON data, they are preparing to submit a New Drug Application (NDA) to the FDA, and if approved, Tyvaso would become the first inhaled anti-fibrotic treatment for IPF, potentially transforming the market.
- Investment Outlook Assessment: While UTHR shows strong investment potential, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, prompting investors to carefully evaluate market dynamics.
See More
United Therapeutics' Tyvaso Shows Positive Results for Lung Fibrosis
- Clinical Trial Results: United Therapeutics announced that the TETON-1 study demonstrated that the inhaled drug Tyvaso significantly improved lung function in patients with idiopathic pulmonary fibrosis, preserving more lung function after one year compared to the placebo group, indicating its substantial potential in enhancing patient health.
- Reduced Disease Progression Risk: The study revealed that patients using Tyvaso experienced a 33% lower risk of their condition worsening, which not only enhances patient quality of life but also provides strong support for the drug's efficacy in clinical applications.
- FDA Approval Plans: United Therapeutics plans to request priority review from the FDA by the end of summer; if granted, Tyvaso could become the first new treatment option for idiopathic pulmonary fibrosis in years, representing significant market potential.
- Partnership Dynamics: MannKind Corporation serves as a manufacturing partner, supplying the dry-powder version of Tyvaso using its Technosphere technology and earning royalties on sales, which will further drive the market promotion and sales of Tyvaso.
See More
Tyvaso Shows Significant Efficacy in Phase 3 IPF Study
- Clinical Trial Success: The TETON-1 study demonstrated that nebulized Tyvaso significantly improved absolute forced vital capacity (FVC) by 130.1 mL at 52 weeks compared to placebo, achieving statistical significance with P<0.001, indicating its efficacy in preserving lung function in IPF patients.
- Reduced Risk of Clinical Deterioration: The results showed that nebulized Tyvaso reduced the risk of clinical worsening by 33% (HR: 0.67; P=0.0034) compared to placebo, providing new treatment hope for IPF patients and potentially altering clinical management strategies.
- Multi-Modal Mechanism of Action: Nebulized Tyvaso combines direct lung delivery with multi-modal activity targeting fibrotic, vascular, and inflammatory pathways not addressed by existing IPF therapies, showcasing its unique advantages in treatment and potentially leading to a new wave of therapeutic innovations.
- FDA Application Plans: United Therapeutics plans to submit a supplemental New Drug Application to the FDA by the end of summer to add IPF to the labeled indications for nebulized Tyvaso, which, if approved, could open new market opportunities and further drive business growth.
See More
Renaissance Technologies Q1 2026 Performance Analysis
- Quarterly Performance: Renaissance Technologies reported a return of -4.58% in Q1 2026, slightly outperforming the S&P 500's decline of 4.63%, indicating its relative resilience despite overall market downturns.
- Portfolio Size: The latest 13F filing reveals a long equity portfolio valued at approximately $63.9 billion across more than 3,200 positions, reflecting the firm's highly diversified and systematic investment strategy.
- Major Holdings: During Q1 2026, the firm's largest holding was United Therapeutics (NASDAQ:UTHR), accounting for 1.66% of the portfolio with a market value of about $1.06 billion, highlighting its significant exposure in the healthcare sector.
- Quant Rating Analysis: Seeking Alpha ranked Renaissance's top 15 holdings, with Micron Technology (MU) receiving a strong buy rating of 4.99, indicating that the company's investments in the tech sector are widely recognized for their potential by the market.
See More
United Therapeutics' Drug Significantly Reduces Risk in Pulmonary Arterial Hypertension
- Significant Clinical Impact: United Therapeutics' investigational drug ralinepag reduces the risk of clinical worsening by 55% compared to placebo in patients with pulmonary arterial hypertension, successfully meeting the primary endpoint and showcasing its therapeutic potential.
- Broad Applicability: The findings were consistent across all patient subgroups, including time since diagnosis, disease etiology, six-minute walk distance (6MWD), WHO/NYHA Functional Class (FC), NT-proBNP levels, and background therapy usage, indicating the broad efficacy of ralinepag.
- Durable Efficacy: In the study population, 80% of patients were on dual background therapy and 70% were classified as WHO/NYHA FC II at baseline, demonstrating ralinepag's durable efficacy in delaying disease progression, which enhances confidence in its clinical application.
- Future Outlook: United Therapeutics anticipates a revenue run rate of $4 billion by the end of 2027, driven by ralinepag and idiopathic pulmonary fibrosis (IPF) plans, further solidifying its market position in the biopharmaceutical sector.
See More
Ralinepag Achieves Breakthrough Results in Pulmonary Arterial Hypertension Study
- Significant Clinical Outcomes: The ADVANCE OUTCOMES study demonstrated that ralinepag achieved a 55% reduction in the risk of clinical worsening in pulmonary arterial hypertension patients (hazard ratio 0.45, p<0.0001), highlighting its potential to improve patient prognosis and potentially transform treatment protocols.
- Biomarker Improvement: The drug significantly reduced N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels by 24.3% (p=0.0013) and improved six-minute walk distance (6MWD) by 20.4 meters (p=0.0033) over 28 weeks, indicating its effectiveness in enhancing cardiac function.
- Good Tolerability: Ralinepag's safety profile was consistent with known prostacyclin-related adverse events, with no new safety signals observed, reinforcing its appeal as a once-daily oral medication for long-term use.
- Future Development Potential: United Therapeutics plans to submit a New Drug Application for ralinepag to the FDA by the second half of 2026, and if approved, it will become the first once-daily oral prostacyclin receptor agonist, potentially significantly improving the quality of life for pulmonary arterial hypertension patients.
See More
United Therapeutics Corporation Ranked Top Stock by Renaissance Technologies
- Portfolio Performance: According to Renaissance Technologies' 13F filings, United Therapeutics Corporation (NASDAQ:UTHR) has consistently appeared in its portfolio since Q4 2014, currently holding nearly 1.8 million shares, although this represents a decrease of over 6% from Q4 2025.
- Clinical Research Breakthrough: The company is making significant strides in the idiopathic pulmonary fibrosis (IPF) space, with the latest TETON study data showing that nebulized Tyvaso significantly improved lung function over 52 weeks, highlighting its potential in the treatment landscape.
- FDA Submission Preparation: Management noted that due to the positive feedback from TETON data, they are preparing to submit a New Drug Application (NDA) to the FDA, and if approved, Tyvaso would become the first inhaled anti-fibrotic treatment for IPF, potentially transforming the market.
- Investment Outlook Assessment: While UTHR shows strong investment potential, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, prompting investors to carefully evaluate market dynamics.
See More
United Therapeutics' Tyvaso Shows Positive Results for Lung Fibrosis
- Clinical Trial Results: United Therapeutics announced that the TETON-1 study demonstrated that the inhaled drug Tyvaso significantly improved lung function in patients with idiopathic pulmonary fibrosis, preserving more lung function after one year compared to the placebo group, indicating its substantial potential in enhancing patient health.
- Reduced Disease Progression Risk: The study revealed that patients using Tyvaso experienced a 33% lower risk of their condition worsening, which not only enhances patient quality of life but also provides strong support for the drug's efficacy in clinical applications.
- FDA Approval Plans: United Therapeutics plans to request priority review from the FDA by the end of summer; if granted, Tyvaso could become the first new treatment option for idiopathic pulmonary fibrosis in years, representing significant market potential.
- Partnership Dynamics: MannKind Corporation serves as a manufacturing partner, supplying the dry-powder version of Tyvaso using its Technosphere technology and earning royalties on sales, which will further drive the market promotion and sales of Tyvaso.
See More
Tyvaso Shows Significant Efficacy in Phase 3 IPF Study
- Clinical Trial Success: The TETON-1 study demonstrated that nebulized Tyvaso significantly improved absolute forced vital capacity (FVC) by 130.1 mL at 52 weeks compared to placebo, achieving statistical significance with P<0.001, indicating its efficacy in preserving lung function in IPF patients.
- Reduced Risk of Clinical Deterioration: The results showed that nebulized Tyvaso reduced the risk of clinical worsening by 33% (HR: 0.67; P=0.0034) compared to placebo, providing new treatment hope for IPF patients and potentially altering clinical management strategies.
- Multi-Modal Mechanism of Action: Nebulized Tyvaso combines direct lung delivery with multi-modal activity targeting fibrotic, vascular, and inflammatory pathways not addressed by existing IPF therapies, showcasing its unique advantages in treatment and potentially leading to a new wave of therapeutic innovations.
- FDA Application Plans: United Therapeutics plans to submit a supplemental New Drug Application to the FDA by the end of summer to add IPF to the labeled indications for nebulized Tyvaso, which, if approved, could open new market opportunities and further drive business growth.
See More
Renaissance Technologies Q1 2026 Performance Analysis
- Quarterly Performance: Renaissance Technologies reported a return of -4.58% in Q1 2026, slightly outperforming the S&P 500's decline of 4.63%, indicating its relative resilience despite overall market downturns.
- Portfolio Size: The latest 13F filing reveals a long equity portfolio valued at approximately $63.9 billion across more than 3,200 positions, reflecting the firm's highly diversified and systematic investment strategy.
- Major Holdings: During Q1 2026, the firm's largest holding was United Therapeutics (NASDAQ:UTHR), accounting for 1.66% of the portfolio with a market value of about $1.06 billion, highlighting its significant exposure in the healthcare sector.
- Quant Rating Analysis: Seeking Alpha ranked Renaissance's top 15 holdings, with Micron Technology (MU) receiving a strong buy rating of 4.99, indicating that the company's investments in the tech sector are widely recognized for their potential by the market.
See More
United Therapeutics' Drug Significantly Reduces Risk in Pulmonary Arterial Hypertension
- Significant Clinical Impact: United Therapeutics' investigational drug ralinepag reduces the risk of clinical worsening by 55% compared to placebo in patients with pulmonary arterial hypertension, successfully meeting the primary endpoint and showcasing its therapeutic potential.
- Broad Applicability: The findings were consistent across all patient subgroups, including time since diagnosis, disease etiology, six-minute walk distance (6MWD), WHO/NYHA Functional Class (FC), NT-proBNP levels, and background therapy usage, indicating the broad efficacy of ralinepag.
- Durable Efficacy: In the study population, 80% of patients were on dual background therapy and 70% were classified as WHO/NYHA FC II at baseline, demonstrating ralinepag's durable efficacy in delaying disease progression, which enhances confidence in its clinical application.
- Future Outlook: United Therapeutics anticipates a revenue run rate of $4 billion by the end of 2027, driven by ralinepag and idiopathic pulmonary fibrosis (IPF) plans, further solidifying its market position in the biopharmaceutical sector.
See More
Ralinepag Achieves Breakthrough Results in Pulmonary Arterial Hypertension Study
- Significant Clinical Outcomes: The ADVANCE OUTCOMES study demonstrated that ralinepag achieved a 55% reduction in the risk of clinical worsening in pulmonary arterial hypertension patients (hazard ratio 0.45, p<0.0001), highlighting its potential to improve patient prognosis and potentially transform treatment protocols.
- Biomarker Improvement: The drug significantly reduced N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels by 24.3% (p=0.0013) and improved six-minute walk distance (6MWD) by 20.4 meters (p=0.0033) over 28 weeks, indicating its effectiveness in enhancing cardiac function.
- Good Tolerability: Ralinepag's safety profile was consistent with known prostacyclin-related adverse events, with no new safety signals observed, reinforcing its appeal as a once-daily oral medication for long-term use.
- Future Development Potential: United Therapeutics plans to submit a New Drug Application for ralinepag to the FDA by the second half of 2026, and if approved, it will become the first once-daily oral prostacyclin receptor agonist, potentially significantly improving the quality of life for pulmonary arterial hypertension patients.
See More
